AIM

Notice of Results and Investor Presentation

Retrieved on: 
Tuesday, March 19, 2024
Webcast, Gold, AIM, Nasdaq Iceland

TORONTO, ONTARIO – March 19, 2024 – Amaroq Minerals Ltd. (AIM, TSXV, NASDAQ Iceland: AMRQ), an independent mine development company with a substantial land package of gold and strategic mineral assets in Southern Greenland, will publish its Full Year results for 2023 on 26 March 2024.

Key Points: 
  • TORONTO, ONTARIO – March 19, 2024 – Amaroq Minerals Ltd. (AIM, TSXV, NASDAQ Iceland: AMRQ), an independent mine development company with a substantial land package of gold and strategic mineral assets in Southern Greenland, will publish its Full Year results for 2023 on 26 March 2024.
  • A remote presentation for sell-side analysts and investors will be held on the same day, at 2:00pm UK Time, followed by an opportunity to ask questions.
  • This will be available for playback after the event.
  • Analysts and investors who wish to participate in the webcast are requested to register via the link here: https://brrmedia.news/AMRQ_FY23

Inside Information: Additional Positive Data from the Phase 1 Part of the BEXMAB Study in Both Higher-Risk HMA-Failed MDS and r/r AML

Retrieved on: 
Monday, March 18, 2024
Principal, Nasdaq First North, Survival, ASH, AML, Associate, Webcast, Patient, Acute myeloid leukemia, Doctor of Philosophy, MD, Quality of life, Myelodysplastic syndrome, Faron Pharmaceuticals, HMA, Myelocyte, Society, Helsinki University Central Hospital, Azacitidine, MDS, MCR, FDA, AIM, SAE, Pharmaceutical industry

TURKU, Finland and BOSTON, March 18, 2024 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company pursuing a CLEVER approach to reprogramming myeloid cells to activate anti-tumor immunity in hematological and solid tumor microenvironments, today provided further data from patients treated during the Phase 1 part of the ongoing BEXMAB trial that has moved into Phase 2 for higher-risk (HR) myelodysplastic syndrome (MDS) patients failed on previous hypomethylating agent (HMA).

Key Points: 
  • Latest readout of the BEXMAB study shows more responding patients and good durability of remission amongst HR HMA-failed MDS patients.
  • 4/5 of the initial Phase 1 HR HMA-failed MDS patients were still alive after eight months of follow-up.
  • Faron will be hosting a virtual webinar to discuss the additional data tomorrow, Tuesday, 19 March at 11.00 EET/9am GMT.
  • After the already reported 5 HMA-failed HR MDS patients, 3 new HMA-failed HR MDS patients were enrolled, filling the remaining Phase 1 slots.

AIM ImmunoTech to Participate in the Virtual Investor Lunch Break: The AIM Opportunity

Retrieved on: 
Friday, March 15, 2024
AIM, Virtual

OCALA, Fla., March 15, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced that it will present at the Virtual Investor Lunch Break: The AIM Opportunity event on Wednesday, March 20, 2024 at 12:00 PM ET.

Key Points: 
  • OCALA, Fla., March 15, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced that it will present at the Virtual Investor Lunch Break: The AIM Opportunity event on Wednesday, March 20, 2024 at 12:00 PM ET.
  • As part of the event, Thomas K. Equels, MS JD, Chief Executive Officer of AIM, will provide a corporate overview, business outlook, and discuss the AIM opportunity.
  • A live video webcast of the presentation will be available on the Events page of the Company’s website ( aimimmuno.com ).
  • A webcast replay will be available two hours following the live presentation and will be accessible for 90 days.

Faron to Host Webcast to Discuss latest data from Phase 1 part of the BEXMAB Study of Bexmarilimab

Retrieved on: 
Thursday, March 14, 2024
Nasdaq First North, AML, Fårö, Associate, Webcast, Patient, Myeloid leukemia, Standard of care, Acute myeloid leukemia, University, Doctor of Philosophy, MD, Myelodysplastic syndrome, Faron Pharmaceuticals, Myelocyte, MDS, AIM

This interactive event will also include an introduction to myeloid leukemia, insights into bexmarilimab’s unique mode of action and the Company’s latest understanding of the early and long-term efficacy of bexmarilimab treatment.

Key Points: 
  • This interactive event will also include an introduction to myeloid leukemia, insights into bexmarilimab’s unique mode of action and the Company’s latest understanding of the early and long-term efficacy of bexmarilimab treatment.
  • Faron will also provide an update on bexmarilimab’s future development pathway and business opportunity.
  • There will be an opportunity to ask questions during the webcast.
  • To register for the event visit: https://faron.videosync.fi/bexmab-study-update/ or contact the IR team for more information at [email protected] .

Faron’s Financial Statement Release January 1 to December 31, 2023

Retrieved on: 
Wednesday, March 13, 2024
Head, Q&A, Survival, Immunotherapy, Patient, Medicine, Standard of care, CMML, Macrophage, Faron Pharmaceuticals, Neoplasm, EET, Rheumatology, PD-1, TME, PR, ASH, AML, Cancer, Johnson & Johnson, Safety, Azacitidine, MDS, BLA, Decitabine, Food, ODD, Nasdaq First North, PD, Tumor microenvironment, Manuscript, CRS, SICAV, MD, Interferon beta-1a, Haematopoietic system, GMT, FDA, AIM, Neurotoxicity, Infection, EUR, Sanofi, SOC, Metabolism, European Hematology Association, EDT, MBA, IPF, Facility, Treasury, Society, Cytokine release syndrome, CPA, Pharmaceutical industry

As at March 13, 2024, the Company is in compliance with all IPF financial covenants as agreed with the waiver letter.

Key Points: 
  • As at March 13, 2024, the Company is in compliance with all IPF financial covenants as agreed with the waiver letter.
  • Loss for the period for the financial year ended December 31, 2023, was EUR 30,9 million (2022: EUR 28,7 million).
  • In June 2023, Faron conducted a placement of 2,601,510 newly issued treasury shares to investors to raise EUR 6,6 million gross.
  • In October 2023, the Company successfully raised EUR 7,1 million gross through the issuance of 2,491,998 ordinary shares to investors.

ARECOR AND TRx BIOSCIENCES ESTABLISH RESEARCH COLLABORATION TO DEVELOP ORAL GLP-1 WITH ENHANCED BIOAVAILABILITY

Retrieved on: 
Tuesday, March 12, 2024
Absorption, Obesity, Diabetes, Human, Patient, Gastrointestinal tract, AREC, Semaglutide, Drug development, TRX, AIM, Peptide, Vaccine

Oral delivery of this class of drug is extremely challenging owing to the proteolytic nature of the digestive system which significantly reduces bioavailability.

Key Points: 
  • Oral delivery of this class of drug is extremely challenging owing to the proteolytic nature of the digestive system which significantly reduces bioavailability.
  • Using TRx Biosciences’ LipiCore™ oral delivery technology alongside Arecor’s formulation platform, Arestat™, the companies intend to jointly develop an oral GLP-1 receptor agonist product with enhanced physicochemical properties that can achieve higher oral bioavailability and stability.
  • Alongside TRx Biosciences and its expertise in targeted oral drug delivery, we have an opportunity to develop an enhanced oral GLP-1 receptor agonist product.
  • Success with semaglutide may offer a path to multiple oral peptide products with enhanced absorption and efficacy.”
    The collaboration provides scope for expansion, following the initial oral GLP-1 receptor agonist programme, to develop further oral peptide products.

Piedmont Lithium Appoints New Board Director

Retrieved on: 
Monday, March 18, 2024
Alternative Vehicles, Fuels, EV, Electric Vehicles, Automotive, Chemicals, Plastics, Automotive Manufacturing, Alternative Energy, Manufacturing, Energy, Mining, Minerals, Natural Resources, Lithium, Piedmont Lithium, Organization, Chair, RTI, Growth, National Space Council, Executive, ALL, History, ASX, PLL, Transport, University, Wilfrid Sellars, RTI International Metals, NASA, Multimedia, AIM, Management

Piedmont Lithium (“Piedmont” or the “Company”) (Nasdaq: PLL; ASX: PLL), a leading global supplier of lithium resources critical to the U.S. electric vehicle (“EV”) supply chain, today announced the appointment of Dawne Hickton to the Board of Directors (“Board”), effective March 14, 2024.

Key Points: 
  • Piedmont Lithium (“Piedmont” or the “Company”) (Nasdaq: PLL; ASX: PLL), a leading global supplier of lithium resources critical to the U.S. electric vehicle (“EV”) supply chain, today announced the appointment of Dawne Hickton to the Board of Directors (“Board”), effective March 14, 2024.
  • View the full release here: https://www.businesswire.com/news/home/20240318562526/en/
    “We are pleased to welcome Dawne to Piedmont’s Board,” said Jeff Armstrong, Chairman of the Company’s Board of Directors.
  • Piedmont Lithium Inc. (Nasdaq: PLL; ASX: PLL) is developing a world-class, multi-asset, integrated lithium business focused on enabling the transition to a net zero world and the creation of a clean energy economy in North America.
  • Our projects include our Carolina Lithium and Tennessee Lithium projects in the United States and partnerships in Quebec with Sayona Mining (ASX: SYA) and in Ghana with Atlantic Lithium (AIM: ALL; ASX: A11).

Getech and Expro Partner to Advance Sustainable Energy Solutions

Retrieved on: 
Wednesday, March 27, 2024
GTC, Geothermal energy, Partnership, Risk, CCS, Carbon, CO2, AIM, Renewable energy

LONDON, March 27, 2024 /PRNewswire-PRWeb/ -- This collaboration brings together Expro's excellence in well evaluation and integrity with Getech's expertise in locating valuable subsurface resources, leveraging proprietary data, geoscience acumen and cutting-edge machine learning technologies. Initially, the primary focus of this partnership is to identify and expedite opportunities within the emerging energy sector, aligning with our shared goals of supporting the transition to a lower carbon future.

Key Points: 
  • Getech (AIM: GTC), a world-leading locator of subsurface resources, has strategically partnered with Expro (NYSE: XPRO), a leading provider of energy services, to propel low-carbon geoenergy projects, including geothermal energy, natural hydrogen and carbon capture and storage (CCS).
  • Our alliance with Expro and access to its well expertise enables us to offer comprehensive solutions in response to the growing demand for renewable energy sources.
  • Together we can address complex energy challenges more efficiently and help organisations decarbonise by offering subsurface low carbon solutions."
  • Ingrid Huldal, Director for Sustainable Energy Solutions, commented:
    "Expro's unwavering commitment to sustainable energy solutions is fully in harmony with Getech's core principles.

accesso® to Power Cutting-Edge Entertainment Destinations Across Saudi Arabia

Retrieved on: 
Wednesday, March 27, 2024
RFID, Financial management, Saudi Vision 2030, Meal, Accesso, NFC, Kingdom, City, API, AIM

TWYFORD, England, March 27, 2024 /PRNewswire/ -- accesso Technology Group (AIM: ACSO), the leading technology solutions provider for attractions and venues worldwide, announced a landmark agreement with Saudi Entertainment Ventures (SEVEN), a wholly owned subsidiary of the Saudi Arabia Public Investment Fund (PIF). In November 2022 – and in alignment with the Kingdom of Saudi Arabia's "Saudi Vision 2030" – SEVEN unveiled plans to introduce 21 cutting-edge entertainment destinations across 14 cities, featuring over 150 attractions, diverse dining outlets, local and international retail outlets that complements the overall entertainment eco-system that SEVEN is spearheading. SEVEN has awarded accesso as the key provider of ticketing and visitor management technology for all destinations and sub-venues associated with the project.  

Key Points: 
  • In November 2022 – and in alignment with the Kingdom of Saudi Arabia's " Saudi Vision 2030 " – SEVEN unveiled plans to introduce 21 cutting-edge entertainment destinations across 14 cities, featuring over 150 attractions, diverse dining outlets, local and international retail outlets that complements the overall entertainment eco-system that SEVEN is spearheading.
  • SEVEN has awarded accesso as the key provider of ticketing and visitor management technology for all destinations and sub-venues associated with the project.
  • "We are honored to be awarded as the key technology partner for SEVEN's growing portfolio of next-generation entertainment destinations," shared accesso CEO Steve Brown.
  • "This opportunity in Saudi Arabia underscores Accesso's commitment to enhancing the guest experience and contributing to the success of projects that are true gamechangers for the leisure & entertainment industry."

accesso® to Power Cutting-Edge Entertainment Destinations Across Saudi Arabia

Retrieved on: 
Wednesday, March 27, 2024
RFID, Financial management, Saudi Vision 2030, Meal, Accesso, NFC, Kingdom, City, API, AIM

TWYFORD, England, March 27, 2024 /PRNewswire/ -- accesso Technology Group (AIM: ACSO), the leading technology solutions provider for attractions and venues worldwide, announced a landmark agreement with Saudi Entertainment Ventures (SEVEN), a wholly owned subsidiary of the Saudi Arabia Public Investment Fund (PIF). In November 2022 – and in alignment with the Kingdom of Saudi Arabia's "Saudi Vision 2030" – SEVEN unveiled plans to introduce 21 cutting-edge entertainment destinations across 14 cities, featuring over 150 attractions, diverse dining outlets, local and international retail outlets that complements the overall entertainment eco-system that SEVEN is spearheading. SEVEN has awarded accesso as the key provider of ticketing and visitor management technology for all destinations and sub-venues associated with the project.  

Key Points: 
  • In November 2022 – and in alignment with the Kingdom of Saudi Arabia's " Saudi Vision 2030 " – SEVEN unveiled plans to introduce 21 cutting-edge entertainment destinations across 14 cities, featuring over 150 attractions, diverse dining outlets, local and international retail outlets that complements the overall entertainment eco-system that SEVEN is spearheading.
  • SEVEN has awarded accesso as the key provider of ticketing and visitor management technology for all destinations and sub-venues associated with the project.
  • "We are honored to be awarded as the key technology partner for SEVEN's growing portfolio of next-generation entertainment destinations," shared accesso CEO Steve Brown.
  • "This opportunity in Saudi Arabia underscores Accesso's commitment to enhancing the guest experience and contributing to the success of projects that are true gamechangers for the leisure & entertainment industry."